NCT03463044View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

August 25, 2016

Study Completion Date

August 25, 2016

Conditions

Healthy Subjects

Interventions

DRUG

nangibotide

Continous i.v. infusion

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

Richmond Pharmacology Ltd., Croydon

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Richmond Pharmacology Limited

INDUSTRY

lead

Inotrem

INDUSTRY